Trial Profile
Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 08 Nov 2018 New trial record